Iptacopan for high-risk TA-TMA after stem cell transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new oral medicine called iptacopan for people who have a serious blood vessel complication after a stem cell transplant (TA-TMA) that is not improving with usual treatments. The goal is to see if iptacopan can help stop the damage and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older.
- You have had a stem cell transplant.
- You have a blood vessel problem called TA-TMA that hasn't gotten better after standard treatments.
- Your TA-TMA is considered high-risk (for example, with very high LDH levels, organ damage, or severe graft-versus-host disease).
- You have not already taken a complement inhibitor (like iptacopan or eculizumab) within the last 60 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
This trial tests whether people with atypical hemolytic uremic syndrome (aHUS) who are doing well on anti-C5 treatment can safely switch to iptacopan. It focuses on both effectiveness (blood counts and kidney function) and safety after the switch.
This trial tests a new drug, iptacopan, for people with autoimmune hemolytic anemia (AIHA) that hasn't responded well to steroids. The goal is to see if it can help raise your red blood cell counts and reduce symptoms.
This trial tests whether eculizumab can safely help people with a serious blood vessel complication called TA-TMA after a stem cell transplant. You may be eligible if you have high-risk features and haven't improved with initial care.
This trial studies whether iptacopan can improve outcomes and safety for people with C3 glomerulopathy, a kidney disease caused by overactive parts of the immune system. Participants must already be on standard kidney-protecting medicines and meet specific kidney function and urine protein criteria.
This trial tests iptacopan (an add-on medicine) in people with idiopathic immune-complex membranoproliferative glomerulonephritis (IC-MPGN), a kidney disease causing significant protein loss in urine. It aims to improve kidney outcomes and safety when added to standard treatments.
Hear when a new Thrombotic Microangiopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.